Kidney and Bladder Cancers :@0.646100:0.035749:0.919881:0.035749:0.919881:0.019993:0.646100:0.019993:0.011372:0.003848:0.013181:0.011738:0.012508:0.010314:0.005330:0.013143:0.011738:0.013181:0.005330:0.011045:0.003848:0.013143:0.013181:0.013181:0.012508:0.005792:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
71:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Postoperative  adjuvant chemotherapy :@0.084848:0.096166:0.481098:0.096166:0.481098:0.080410:0.084848:0.080410:0.011392:0.012604:0.007466:0.006523:0.012604:0.013123:0.012508:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.013537:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.018877:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
has been studied in several small phase III :@0.084848:0.112583:0.481088:0.112583:0.481088:0.096827:0.084848:0.096827:0.011738:0.013143:0.007466:0.006004:0.013123:0.012508:0.012508:0.011738:0.006004:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.013181:0.006004:0.003848:0.011738:0.006004:0.007466:0.012508:0.010660:0.012508:0.005792:0.013143:0.003848:0.006004:0.007466:0.018049:0.013143:0.003848:0.003848:0.006015:0.013123:0.011738:0.013143:0.007466:0.012508:0.005357:0.004349:0.004349:0.004349:0.005330
trials as an alternative to neoadjuvant :@0.084848:0.129000:0.481065:0.129000:0.481065:0.113244:0.084848:0.113244:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.012835:0.013143:0.007466:0.012835:0.013143:0.011738:0.012835:0.013143:0.003848:0.006523:0.012508:0.006192:0.011738:0.013143:0.006523:0.003848:0.010660:0.012508:0.012835:0.006523:0.012604:0.012835:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330
treatment.  Meta-analyses  of these trials :@0.084848:0.145418:0.481099:0.145418:0.481099:0.129662:0.084848:0.129662:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.005330:0.006279:0.017684:0.012508:0.006523:0.013143:0.006388:0.013143:0.011738:0.013143:0.003848:0.010314:0.007466:0.012508:0.007466:0.005330:0.006304:0.012604:0.006042:0.011622:0.006523:0.011738:0.012508:0.007466:0.012508:0.011622:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.005330
suggest  a  survival  benefit  when  patients :@0.084848:0.161835:0.481084:0.161835:0.481084:0.146079:0.084848:0.146079:0.007466:0.011699:0.012950:0.012950:0.012508:0.007466:0.006523:0.005330:0.003960:0.013143:0.005330:0.003966:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.003977:0.013123:0.012508:0.011738:0.012508:0.004686:0.004686:0.006523:0.005330:0.003952:0.015990:0.011738:0.012508:0.011738:0.005330:0.003960:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
are given chemotherapy following radical :@0.084848:0.178253:0.481088:0.178253:0.481088:0.162497:0.084848:0.162497:0.013143:0.005715:0.012508:0.004618:0.012950:0.003848:0.010660:0.012508:0.011738:0.004618:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004618:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.004618:0.005792:0.013143:0.013181:0.003848:0.012450:0.013143:0.003848:0.005330
cystectomy. This is a reasonable option for :@0.084848:0.194670:0.481096:0.194670:0.481096:0.178914:0.084848:0.178914:0.012450:0.010314:0.007466:0.006523:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330:0.005003:0.008197:0.011738:0.003848:0.007466:0.005003:0.003848:0.007466:0.005003:0.013143:0.005003:0.005713:0.012508:0.013143:0.007466:0.012604:0.011738:0.013143:0.013123:0.003848:0.012508:0.005003:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.004993:0.006042:0.012604:0.005792:0.005330
high-risk patients who have not had neo-:@0.084848:0.211087:0.475758:0.211087:0.475758:0.195331:0.084848:0.195331:0.011738:0.003848:0.012950:0.011738:0.006388:0.005792:0.003848:0.007466:0.009660:0.007012:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007023:0.015990:0.011738:0.012604:0.007008:0.011738:0.013143:0.010660:0.012508:0.007014:0.011738:0.012604:0.006523:0.007008:0.011738:0.013143:0.013181:0.007014:0.011738:0.012508:0.012588:0.006388
adjuvant chemotherapy.:@0.084848:0.227505:0.319991:0.227505:0.319991:0.211749:0.084848:0.211749:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
Most  patients with  bladder cancer :@0.103032:0.243922:0.481105:0.243922:0.481105:0.228166:0.103032:0.228166:0.017684:0.012604:0.007466:0.006523:0.005330:0.012823:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.018165:0.015990:0.003848:0.006523:0.011738:0.005330:0.012825:0.013123:0.003848:0.013143:0.013181:0.013181:0.012508:0.005792:0.018165:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
would,  if possible, prefer  to keep  their :@0.084848:0.260340:0.481111:0.260340:0.481111:0.244584:0.084848:0.244584:0.015990:0.012604:0.011699:0.003848:0.013181:0.005330:0.005330:0.007341:0.003848:0.006042:0.012681:0.013123:0.012604:0.007466:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330:0.012681:0.013123:0.005715:0.012508:0.006042:0.012508:0.005792:0.005330:0.007335:0.006523:0.012604:0.012681:0.009660:0.012508:0.012508:0.013123:0.005330:0.007341:0.006523:0.011738:0.012508:0.003848:0.005792:0.005330
native bladder. Use of  multimodal ap-:@0.084848:0.276757:0.475760:0.276757:0.475760:0.261001:0.084848:0.261001:0.011738:0.013143:0.006523:0.003848:0.010660:0.012508:0.013027:0.013123:0.003848:0.013143:0.013181:0.013181:0.012508:0.004380:0.005330:0.013027:0.012604:0.007466:0.012508:0.013027:0.012604:0.006042:0.005330:0.007687:0.018049:0.011699:0.003848:0.006523:0.003848:0.018049:0.012604:0.013181:0.013143:0.003848:0.013027:0.013143:0.013123:0.006388
proaches,  including  complete  TURBT,  ra-:@0.084848:0.293174:0.475758:0.293174:0.475758:0.277418:0.084848:0.277418:0.013123:0.005715:0.012604:0.013143:0.012450:0.011738:0.012508:0.007466:0.005330:0.005330:0.004545:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330:0.004551:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.005330:0.004551:0.008197:0.012604:0.011680:0.011045:0.006223:0.005330:0.005330:0.004549:0.005792:0.013143:0.006388
diation therapy, and chemotherapy, used :@0.084848:0.309592:0.481111:0.309592:0.481111:0.293836:0.084848:0.293836:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.004714:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004714:0.013143:0.011738:0.013181:0.004714:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011722:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.004714:0.011699:0.007466:0.012508:0.013181:0.005330
together  or in sequence, offers an alter-:@0.084848:0.326009:0.475754:0.326009:0.475754:0.310253:0.084848:0.310253:0.006523:0.012604:0.012950:0.012508:0.006523:0.011738:0.012508:0.005792:0.005330:0.003466:0.012604:0.005792:0.008813:0.003848:0.011738:0.008813:0.007466:0.012508:0.013123:0.011699:0.012508:0.011738:0.012450:0.012508:0.005330:0.008813:0.012604:0.006094:0.006042:0.012508:0.005792:0.007466:0.008813:0.013143:0.011738:0.008813:0.013143:0.003848:0.006523:0.012508:0.005792:0.006388
native to radical  cystectomy, preserving :@0.084848:0.342427:0.481080:0.342427:0.481080:0.326671:0.084848:0.326671:0.011738:0.013143:0.006523:0.003848:0.010660:0.012508:0.009275:0.006523:0.012604:0.009275:0.005792:0.013143:0.013181:0.003848:0.012450:0.013143:0.003848:0.005330:0.003956:0.012450:0.010314:0.007466:0.006523:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330:0.009275:0.013123:0.005715:0.012508:0.007466:0.012508:0.005792:0.010660:0.003848:0.011738:0.012950:0.005330
the bladder and its function while provid-:@0.084848:0.358844:0.475746:0.358844:0.475746:0.343088:0.084848:0.343088:0.006523:0.011738:0.012508:0.006562:0.013123:0.003848:0.013143:0.013181:0.013181:0.012508:0.005792:0.006562:0.013143:0.011738:0.013181:0.006562:0.003848:0.006523:0.007466:0.006562:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.006550:0.015990:0.011738:0.003848:0.003848:0.012508:0.006562:0.013123:0.005715:0.012604:0.010660:0.003848:0.013181:0.006388
ing long-term disease control for carefully :@0.084848:0.375261:0.481090:0.375261:0.481090:0.359505:0.084848:0.359505:0.003848:0.011738:0.012950:0.006369:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006313:0.018049:0.006369:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.006381:0.012450:0.012604:0.011738:0.006523:0.005703:0.012604:0.003848:0.006369:0.006042:0.012604:0.005792:0.006369:0.012450:0.013143:0.005715:0.012508:0.006042:0.011699:0.003848:0.003848:0.010314:0.005330
selected patients. The pooled analysis of :@0.084848:0.391679:0.481086:0.391679:0.481086:0.375923:0.084848:0.375923:0.007466:0.012508:0.003848:0.012508:0.012450:0.006523:0.012508:0.013181:0.007966:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.007953:0.008197:0.011738:0.012508:0.007949:0.013123:0.012604:0.012604:0.003848:0.012508:0.013181:0.007957:0.013143:0.011738:0.013143:0.003848:0.010314:0.007466:0.003848:0.007466:0.007966:0.012604:0.006042:0.005330
the RTOG (2014)  included 468  patients :@0.084848:0.408096:0.481072:0.408041:0.481072:0.392285:0.084848:0.392340:0.006523:0.011738:0.012508:0.009602:0.011792:0.008197:0.016722:0.016779:0.009602:0.007100:0.010660:0.010660:0.010674:0.010660:0.007100:0.012445:0.009602:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.013181:0.009602:0.010660:0.010660:0.010660:0.005330:0.004289:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.408207
13:@0.245177:0.402422:0.257607:0.402422:0.257607:0.393236:0.245177:0.393236:0.006215:0.006215
who  had chemo-radiation;  the  response :@0.084853:0.424458:0.481106:0.424458:0.481106:0.408702:0.084853:0.408702:0.015990:0.011738:0.012604:0.005330:0.003604:0.011738:0.013143:0.013181:0.008948:0.012450:0.011738:0.012508:0.018049:0.012604:0.006388:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.003602:0.006523:0.011738:0.012508:0.005330:0.003604:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330
rate was 69% and disease-specific control :@0.084853:0.440875:0.481091:0.440875:0.481091:0.425120:0.084853:0.425120:0.005792:0.013143:0.006523:0.012508:0.005761:0.015990:0.013143:0.007466:0.005771:0.010660:0.010660:0.014913:0.005773:0.013143:0.011738:0.013181:0.005769:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.006388:0.007466:0.013123:0.012523:0.012450:0.003848:0.004686:0.004686:0.012450:0.005765:0.012450:0.012604:0.011738:0.006523:0.005703:0.012604:0.003848:0.005330
rates were 71% at five years.:@0.084853:0.457293:0.346637:0.457293:0.346637:0.441537:0.084853:0.441537:0.005792:0.013143:0.006523:0.012508:0.007466:0.005330:0.015990:0.012508:0.005705:0.012508:0.005330:0.010660:0.010660:0.014913:0.005330:0.013143:0.006523:0.005330:0.004686:0.004686:0.010660:0.012508:0.005330:0.010314:0.012508:0.013143:0.005792:0.007466:0.005330
Patients with extensive comorbid dis-:@0.103037:0.473710:0.475763:0.473710:0.475763:0.457954:0.103037:0.457954:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.012989:0.015990:0.003848:0.006523:0.011738:0.012989:0.012508:0.009236:0.006523:0.012508:0.011738:0.007466:0.003848:0.010660:0.012508:0.012989:0.012450:0.012604:0.018049:0.012604:0.005792:0.013123:0.003848:0.013181:0.012989:0.013181:0.003848:0.007466:0.006388
ease, or those who are otherwise not can-:@0.084853:0.490128:0.475772:0.490128:0.475772:0.474372:0.084853:0.474372:0.012508:0.013143:0.007466:0.012508:0.005330:0.005080:0.012604:0.005792:0.005063:0.006523:0.011738:0.012604:0.007466:0.012508:0.005065:0.015990:0.011738:0.012604:0.005067:0.013143:0.005715:0.012508:0.005070:0.012604:0.006523:0.011738:0.012508:0.005792:0.015977:0.003848:0.007466:0.012508:0.005080:0.011738:0.012604:0.006523:0.005063:0.012450:0.013143:0.011738:0.006388
didates for radical cystectomy, could be :@0.084853:0.506545:0.481106:0.506545:0.481106:0.490789:0.084853:0.490789:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.007466:0.006042:0.012604:0.005792:0.007445:0.005792:0.013143:0.013181:0.003848:0.012450:0.013143:0.003848:0.007466:0.012450:0.010314:0.007466:0.006523:0.012508:0.012450:0.006523:0.012604:0.018049:0.010314:0.005330:0.007455:0.012450:0.012604:0.011699:0.003848:0.013181:0.007455:0.013123:0.012508:0.005330
considered for radiotherapy, with or with-:@0.084853:0.522962:0.475765:0.522962:0.475765:0.507207:0.084853:0.507207:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005711:0.012508:0.013181:0.006658:0.006042:0.012604:0.005792:0.006646:0.005792:0.013143:0.013181:0.003848:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006648:0.015990:0.003848:0.006523:0.011738:0.006658:0.012604:0.005792:0.006646:0.015990:0.003848:0.006523:0.011738:0.006388
out chemotherapy, or alternatively chem-:@0.084853:0.539380:0.475782:0.539380:0.475782:0.523624:0.084853:0.523624:0.012604:0.011699:0.006523:0.004984:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005777:0.013143:0.013123:0.010314:0.005330:0.005003:0.012604:0.005792:0.004984:0.013143:0.003848:0.006523:0.012508:0.006192:0.011738:0.013143:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005003:0.012450:0.011738:0.012508:0.018049:0.006388
otherapy alone.:@0.084853:0.555797:0.235098:0.555797:0.235098:0.540041:0.084853:0.540041:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330
Metastatic disease: chemotherapy :@0.084848:0.588923:0.451309:0.588923:0.451309:0.570902:0.084848:0.570902:0.019242:0.013683:0.006414:0.014111:0.009407:0.006414:0.014111:0.006414:0.005131:0.013683:0.005987:0.014111:0.005131:0.009407:0.013683:0.014111:0.009407:0.013683:0.005987:0.005987:0.013683:0.012828:0.013683:0.020098:0.013683:0.006414:0.012828:0.013683:0.006842:0.014111:0.014111:0.012401:0.005987
and immunotherapy:@0.084848:0.606812:0.296942:0.606812:0.296942:0.588791:0.084848:0.588791:0.014111:0.012828:0.014111:0.005987:0.005131:0.020098:0.020098:0.012828:0.012828:0.013683:0.006414:0.012828:0.013683:0.006842:0.014111:0.014111:0.012401
A cisplatin-based combination chemo-:@0.084848:0.624369:0.475758:0.624369:0.475758:0.608613:0.084848:0.608613:0.014239:0.013816:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.006388:0.013123:0.013143:0.007489:0.012508:0.013181:0.013816:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.013816:0.012450:0.011738:0.012508:0.018049:0.012600:0.006388
therapy regimen is the preferred initial ther-:@0.084848:0.640786:0.475758:0.640786:0.475758:0.625030:0.084848:0.625030:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.003589:0.005711:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.003587:0.003848:0.007466:0.003598:0.006523:0.011738:0.012508:0.003585:0.013123:0.005715:0.012508:0.006042:0.012508:0.005792:0.005703:0.012508:0.013181:0.003598:0.003848:0.011738:0.003848:0.006523:0.003848:0.013143:0.003848:0.003598:0.006523:0.011738:0.012508:0.005784:0.006388
apy for patients with metastatic urothelial :@0.084848:0.657204:0.481074:0.657204:0.481074:0.641448:0.084848:0.641448:0.013143:0.013123:0.010314:0.006254:0.006042:0.012604:0.005792:0.006244:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006254:0.015990:0.003848:0.006523:0.011738:0.006254:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.006254:0.011699:0.005711:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.005330
cancer who are cisplatin candidates. Cis-:@0.084848:0.673621:0.475739:0.673621:0.475739:0.657865:0.084848:0.657865:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005850:0.015990:0.011738:0.012604:0.005850:0.013143:0.005715:0.012508:0.005850:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005869:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.005330:0.005850:0.015644:0.003848:0.007466:0.006388
platin-based combination chemotherapy :@0.084848:0.690038:0.481096:0.690038:0.481096:0.674282:0.084848:0.674282:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.006369:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.006358:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
results in superior survival when compared :@0.084848:0.706456:0.481101:0.706456:0.481101:0.690700:0.084848:0.690700:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.005484:0.003848:0.011738:0.005484:0.007466:0.011699:0.013123:0.012508:0.005792:0.003848:0.012604:0.005792:0.005484:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005484:0.015990:0.011738:0.012508:0.011738:0.005484:0.012450:0.012604:0.018049:0.013123:0.013143:0.005711:0.012508:0.013181:0.005330
with single-agent cisplatin. Not all patients :@0.084848:0.722873:0.481082:0.722873:0.481082:0.707117:0.084848:0.707117:0.015990:0.003848:0.006523:0.011738:0.005359:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.005355:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.005369:0.014239:0.012594:0.006523:0.005357:0.013143:0.003848:0.003848:0.005369:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with urothelial cancer  are appropriate :@0.084848:0.739290:0.481098:0.739290:0.481098:0.723535:0.084848:0.723535:0.015990:0.003848:0.006523:0.011738:0.013816:0.011699:0.005711:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.013816:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.008476:0.013143:0.005715:0.012508:0.013816:0.013143:0.013123:0.013123:0.005719:0.012604:0.013123:0.005792:0.003848:0.013143:0.006523:0.012508:0.005330
candidates for cisplatin therapy.:@0.084848:0.755708:0.386916:0.755708:0.386916:0.739952:0.084848:0.739952:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.005330:0.006042:0.012604:0.005792:0.005330:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
Other regimens include MVAC (metho-:@0.103032:0.772125:0.475758:0.772125:0.475758:0.756369:0.103032:0.756369:0.016722:0.006523:0.011738:0.012508:0.005792:0.007936:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.007947:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007947:0.017684:0.011161:0.014239:0.015644:0.007947:0.007100:0.018049:0.012508:0.006523:0.011738:0.012579:0.006388
trexate,  vinblastine, doxorubicin and cis-:@0.084848:0.788543:0.475773:0.788543:0.475773:0.772787:0.084848:0.772787:0.006523:0.005709:0.012508:0.009236:0.013143:0.006523:0.012508:0.005330:0.005330:0.003991:0.010660:0.003848:0.011738:0.013123:0.003848:0.013156:0.007466:0.006523:0.003848:0.011738:0.012508:0.005330:0.009333:0.013181:0.012604:0.009236:0.012604:0.005792:0.011699:0.013123:0.003848:0.012450:0.003848:0.011738:0.009333:0.013143:0.011738:0.013181:0.009333:0.012450:0.003848:0.007466:0.006388
platin) or GC (gemcitabine and cisplatin). :@0.084848:0.804960:0.481063:0.804960:0.481063:0.789204:0.084848:0.789204:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.007100:0.005305:0.012604:0.005792:0.005292:0.016779:0.015644:0.005292:0.007100:0.012950:0.012508:0.018049:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005292:0.013143:0.011738:0.013181:0.005292:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.007100:0.005330:0.005330
Given the similar efficacy and lesser toxic-:@0.084848:0.821377:0.475765:0.821377:0.475765:0.805622:0.084848:0.805622:0.016779:0.003848:0.010660:0.012508:0.011738:0.005609:0.006523:0.011738:0.012508:0.005603:0.007466:0.003848:0.018049:0.003848:0.003848:0.013158:0.005792:0.005601:0.012508:0.006042:0.004686:0.004686:0.012450:0.013143:0.012450:0.010314:0.005601:0.013143:0.011738:0.013181:0.005605:0.003848:0.012508:0.007466:0.007466:0.012508:0.005792:0.005607:0.006523:0.012604:0.009236:0.003848:0.012450:0.006388
ity, GC rather than MVAC is often consid-:@0.084848:0.837795:0.475771:0.837795:0.475771:0.822039:0.084848:0.822039:0.003848:0.006523:0.010314:0.005330:0.006677:0.016779:0.015644:0.006677:0.005792:0.013143:0.006523:0.011738:0.012508:0.005792:0.006662:0.006523:0.011738:0.013143:0.011738:0.006677:0.017684:0.011161:0.014239:0.015644:0.006677:0.003848:0.007466:0.006677:0.012604:0.006042:0.006523:0.012508:0.011738:0.006667:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.006388
ered as the standard first-line regimen for :@0.084848:0.854212:0.481092:0.854212:0.481092:0.838456:0.084848:0.838456:0.012508:0.005711:0.012508:0.013181:0.007058:0.013143:0.007466:0.007060:0.006523:0.011738:0.012508:0.007052:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005677:0.013181:0.007060:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.007060:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007052:0.006042:0.012604:0.005792:0.005330
patients  with  advanced urothelial carci-:@0.084848:0.870630:0.475771:0.870630:0.475771:0.854874:0.084848:0.854874:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.004301:0.015990:0.003848:0.006523:0.011738:0.005330:0.004297:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.009640:0.011699:0.005711:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.009640:0.012450:0.013143:0.005659:0.012450:0.003848:0.006388
noma of the bladder.:@0.084848:0.887047:0.284463:0.887047:0.284463:0.871291:0.084848:0.871291:0.011738:0.012604:0.018049:0.013143:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.013123:0.003848:0.013143:0.013181:0.013181:0.012508:0.004362:0.005330
14:@0.284460:0.881381:0.296890:0.881381:0.296890:0.872196:0.284460:0.872196:0.006215:0.006215
For those patients who are candidates for :@0.103030:0.903415:0.481144:0.903415:0.481144:0.887659:0.103030:0.887659:0.008755:0.012027:0.005215:0.005946:0.005946:0.011161:0.012027:0.006889:0.011930:0.005946:0.012546:0.012565:0.005946:0.003271:0.011930:0.011161:0.005946:0.006889:0.005946:0.015413:0.011161:0.012027:0.005946:0.012565:0.005134:0.011930:0.005936:0.011873:0.012565:0.011161:0.012604:0.003271:0.012604:0.012565:0.005946:0.011930:0.006889:0.005946:0.005465:0.012027:0.005786:0.005330
chemotherapy, but not able to receive cispl-:@0.084846:0.919832:0.475752:0.919832:0.475752:0.904076:0.084846:0.904076:0.011873:0.011161:0.011930:0.017472:0.012027:0.005946:0.011161:0.011930:0.005215:0.012565:0.012546:0.009737:0.004753:0.004195:0.012546:0.011122:0.005946:0.004195:0.011161:0.012027:0.005946:0.004195:0.012565:0.012546:0.003271:0.011930:0.004195:0.005946:0.012027:0.004195:0.005134:0.011930:0.011873:0.011930:0.003271:0.010083:0.011930:0.004195:0.011873:0.003271:0.006889:0.012546:0.003271:0.006388
atin, usually because of poor renal function, :@0.084846:0.936250:0.481099:0.936250:0.481099:0.920494:0.084846:0.920494:0.012565:0.005946:0.003271:0.011161:0.004753:0.005946:0.011122:0.006889:0.011122:0.012565:0.003271:0.003271:0.009737:0.005946:0.012546:0.011930:0.011873:0.012565:0.011122:0.006889:0.011930:0.005946:0.012027:0.005465:0.005946:0.012546:0.012027:0.012027:0.005215:0.005946:0.005136:0.011930:0.011161:0.012565:0.003271:0.005946:0.005465:0.011122:0.011161:0.011873:0.005946:0.003271:0.012027:0.011161:0.005326:0.005330
the combination of gemcitabine and carbo-:@0.524246:0.096171:0.915194:0.096171:0.915194:0.080415:0.524246:0.080415:0.005946:0.011161:0.011930:0.003964:0.011873:0.012027:0.017472:0.012546:0.003271:0.011161:0.012565:0.005946:0.003271:0.012027:0.011161:0.003964:0.012027:0.005465:0.003964:0.012373:0.011930:0.017472:0.011873:0.003271:0.005946:0.012565:0.012546:0.003271:0.011161:0.011930:0.003964:0.012565:0.011161:0.012604:0.003964:0.011873:0.012565:0.005215:0.012546:0.012027:0.006388
platin is a reasonable alternative.:@0.524246:0.112615:0.814376:0.112615:0.814376:0.096859:0.524246:0.096859:0.012546:0.003271:0.012565:0.005946:0.003271:0.011161:0.004753:0.003271:0.006889:0.004753:0.012565:0.004753:0.005136:0.011930:0.012565:0.006889:0.012027:0.011161:0.012565:0.012546:0.003271:0.011930:0.004753:0.012565:0.003271:0.005946:0.011930:0.005613:0.011161:0.012565:0.005946:0.003271:0.010083:0.011930:0.005330
15:@0.813804:0.106990:0.825898:0.106990:0.825898:0.097804:0.813804:0.097804:0.005878:0.006215
Single-agent  therapy  or  taxane-based :@0.542424:0.129052:0.920477:0.129052:0.920477:0.113296:0.542424:0.113296:0.009583:0.003848:0.011738:0.012950:0.003848:0.012508:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.005124:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005126:0.012604:0.005792:0.005330:0.005122:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330
regimens could be considered for  these :@0.524240:0.145496:0.920500:0.145496:0.920500:0.129740:0.524240:0.129740:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.009275:0.012450:0.012604:0.011699:0.003848:0.013181:0.009275:0.013123:0.012508:0.009275:0.012450:0.012604:0.011738:0.007466:0.003848:0.013181:0.012508:0.005713:0.012508:0.013181:0.009275:0.006042:0.012604:0.005792:0.005330:0.003931:0.006523:0.011738:0.012508:0.007466:0.012508:0.005330
patients. The  combination  of  gemcit-:@0.524240:0.161940:0.915155:0.161940:0.915155:0.146184:0.524240:0.146184:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.016818:0.008197:0.011738:0.012508:0.005330:0.011474:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.011478:0.012604:0.006042:0.005330:0.011478:0.012950:0.012508:0.018049:0.012450:0.003848:0.006523:0.006388
abine  with a taxane rather  than a plati-:@0.524240:0.178384:0.915120:0.178384:0.915120:0.162628:0.524240:0.162628:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330:0.003290:0.015990:0.003848:0.006523:0.011738:0.008621:0.013143:0.008621:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.008621:0.005792:0.013143:0.006523:0.011738:0.012508:0.005792:0.005330:0.003281:0.006523:0.011738:0.013143:0.011738:0.008621:0.013143:0.008621:0.013123:0.003848:0.013143:0.006523:0.003848:0.006388
num  has been  evaluated, with  encour-:@0.524240:0.194828:0.915156:0.194825:0.915156:0.179070:0.524240:0.179072:0.011738:0.011699:0.018049:0.005330:0.003602:0.011738:0.013143:0.007466:0.008948:0.013123:0.012508:0.012508:0.011738:0.005330:0.003608:0.012508:0.010660:0.013143:0.003848:0.011699:0.013143:0.006523:0.012508:0.013181:0.005330:0.017639:0.015990:0.003848:0.006523:0.011738:0.005330:0.003608:0.012508:0.011738:0.012450:0.012604:0.011699:0.005782:0.285312
16 :@0.777304:0.189206:0.792841:0.189206:0.792841:0.180021:0.777304:0.180021:0.006215:0.006215:0.003107
aging results.:@0.524247:0.211269:0.644754:0.211269:0.644754:0.195513:0.524247:0.195513:0.013143:0.012950:0.003848:0.011738:0.012950:0.005330:0.005707:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.005330
Since up to  50% of  patients with ad-:@0.542431:0.227713:0.915173:0.227713:0.915173:0.211957:0.542431:0.211957:0.009583:0.003848:0.011738:0.012450:0.012508:0.011161:0.011699:0.013123:0.011161:0.006523:0.012604:0.005330:0.005819:0.010660:0.010660:0.014913:0.011161:0.012604:0.006042:0.005330:0.005821:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.011161:0.015990:0.003848:0.006523:0.011738:0.011161:0.013143:0.013181:0.006388
vanced RCC are not  candidates for :@0.524247:0.244157:0.920496:0.244157:0.920496:0.228401:0.524247:0.228401:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.016087:0.011680:0.015644:0.015644:0.016087:0.013143:0.005715:0.012508:0.016087:0.011738:0.012604:0.006523:0.005330:0.010747:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.016087:0.006042:0.012604:0.005792:0.005330
chemotherapy  due to age or  comor-:@0.524247:0.260601:0.915156:0.260601:0.915156:0.244845:0.524247:0.244845:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.008471:0.013181:0.011699:0.012508:0.013816:0.006523:0.012604:0.013816:0.013143:0.012950:0.012508:0.013816:0.012604:0.005792:0.005330:0.008474:0.012450:0.012604:0.018049:0.012604:0.005761:0.006388
bidities (e.g., renal function, heart failure, :@0.524247:0.277045:0.920488:0.277045:0.920488:0.261289:0.524247:0.261289:0.013123:0.003848:0.013181:0.003848:0.006523:0.003848:0.012508:0.007466:0.007466:0.007100:0.012508:0.005330:0.012950:0.005330:0.005330:0.007445:0.005713:0.012508:0.011738:0.013143:0.003848:0.007456:0.006042:0.011699:0.011738:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.007441:0.011738:0.012508:0.013143:0.005792:0.006523:0.007445:0.006042:0.013143:0.003848:0.003848:0.011699:0.005719:0.012508:0.005330:0.005330
neuropathy and so on), immunotherapies :@0.524247:0.293489:0.920500:0.293489:0.920500:0.277733:0.524247:0.277733:0.011738:0.012508:0.011699:0.005707:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314:0.006069:0.013143:0.011738:0.013181:0.006081:0.007466:0.012604:0.006071:0.012604:0.011738:0.007100:0.005330:0.006065:0.003848:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.007466:0.005330
were  investigated  and  reported  great :@0.524247:0.309932:0.920482:0.309932:0.920482:0.294177:0.524247:0.294177:0.015990:0.012508:0.005711:0.012508:0.005330:0.009284:0.003848:0.011738:0.010660:0.012508:0.007466:0.006523:0.003848:0.012950:0.013143:0.006523:0.012508:0.013181:0.005330:0.009283:0.013143:0.011738:0.013181:0.005330:0.009284:0.005713:0.012508:0.013123:0.012604:0.005792:0.006523:0.012508:0.013181:0.005330:0.009273:0.012950:0.005711:0.012508:0.013143:0.006523:0.005330
phase II data.:@0.524247:0.326376:0.652901:0.326376:0.652901:0.310620:0.524247:0.310620:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.004349:0.004349:0.005330:0.013181:0.013143:0.006523:0.013143:0.005330
PD-1 inhibitors (pembrolizumab and :@0.542431:0.342820:0.920490:0.342820:0.920490:0.327064:0.542431:0.327064:0.011392:0.014316:0.006388:0.010660:0.019088:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.019088:0.007100:0.013123:0.012508:0.018049:0.013123:0.005719:0.012604:0.003848:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.019088:0.013143:0.011738:0.013181:0.005330
nivolumab) and PD-L1 inhibitors (atezolu-:@0.524247:0.359264:0.915156:0.359264:0.915156:0.343508:0.524247:0.343508:0.011738:0.003848:0.010660:0.012604:0.003848:0.011699:0.018049:0.013143:0.013123:0.007100:0.008217:0.013143:0.011738:0.013181:0.008217:0.011392:0.014316:0.006388:0.008890:0.010660:0.008217:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.008217:0.007100:0.013143:0.006523:0.012508:0.008178:0.012604:0.003848:0.011699:0.006388
zimab, avelumab and durvalumab) have :@0.524247:0.375708:0.920459:0.375708:0.920459:0.359952:0.524247:0.359952:0.008178:0.003848:0.018049:0.013143:0.013123:0.005330:0.006369:0.013143:0.010660:0.012508:0.003848:0.011699:0.018049:0.013143:0.013123:0.006369:0.013143:0.011738:0.013181:0.006369:0.013181:0.011699:0.005792:0.010660:0.013143:0.003848:0.011699:0.018049:0.013143:0.013123:0.007100:0.006381:0.011738:0.013143:0.010660:0.012508:0.005330
all shown survival advantage in trials in the :@0.524247:0.392152:0.920475:0.392152:0.920475:0.376396:0.524247:0.376396:0.013143:0.003848:0.003848:0.004845:0.007466:0.011738:0.012604:0.015990:0.011738:0.004830:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.004849:0.013143:0.013181:0.010660:0.013143:0.011738:0.006523:0.013143:0.012950:0.012508:0.004830:0.003848:0.011738:0.004830:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.004841:0.003848:0.011738:0.004830:0.006523:0.011738:0.012508:0.005330
second-line setting and acceptable toxic-:@0.524247:0.408596:0.915166:0.408596:0.915166:0.392840:0.524247:0.392840:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.003848:0.003848:0.011738:0.012508:0.004791:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.004782:0.013143:0.011738:0.013181:0.004791:0.013143:0.012450:0.012450:0.012508:0.013123:0.006523:0.013143:0.013123:0.003848:0.012508:0.004791:0.006523:0.012604:0.009236:0.003848:0.012450:0.006388
ity. Phase III trials are currently being run :@0.524247:0.425039:0.920515:0.425039:0.920515:0.409283:0.524247:0.409283:0.003848:0.006523:0.010314:0.005330:0.008524:0.011392:0.011738:0.013143:0.007466:0.012508:0.008524:0.004349:0.004349:0.004349:0.008524:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.008524:0.013143:0.005715:0.012508:0.008524:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.006523:0.003848:0.010314:0.008524:0.013123:0.012508:0.003848:0.011738:0.012950:0.008524:0.005792:0.011699:0.011738:0.005330
to test these drugs in the first-line setting, :@0.524247:0.441483:0.920500:0.441483:0.920500:0.425727:0.524247:0.425727:0.006523:0.012604:0.008028:0.006523:0.012508:0.007466:0.006523:0.008032:0.006523:0.011738:0.012508:0.007466:0.012508:0.008028:0.013181:0.005792:0.011699:0.012950:0.007466:0.008030:0.003848:0.011738:0.008036:0.006523:0.011738:0.012508:0.008028:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.008039:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330:0.005330
adjuvant and neoadjuvant setting.:@0.524247:0.457927:0.850021:0.457927:0.850021:0.442171:0.524247:0.442171:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.013143:0.011738:0.013181:0.005330:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330
SECOND-LINE THERAPY:@0.524242:0.491128:0.757289:0.491128:0.757289:0.473313:0.524242:0.473313:0.011118:0.011118:0.016677:0.017960:0.015822:0.014966:0.008980:0.009407:0.005987:0.015822:0.011118:0.005987:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256
Although a significant number of patients :@0.524242:0.508718:0.920483:0.508718:0.920483:0.492962:0.524242:0.492962:0.014239:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.006573:0.013143:0.006592:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.006589:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.006585:0.012604:0.006042:0.006587:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
responds  objectively  to  first-line  therapy, :@0.524242:0.525162:0.920489:0.525162:0.920489:0.509406:0.524242:0.509406:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.007466:0.005330:0.004607:0.012604:0.013123:0.003906:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005330:0.004614:0.006523:0.012604:0.005330:0.004599:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330:0.004605:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330
most  eventually progress (median surviv-:@0.524242:0.541606:0.915149:0.541606:0.915149:0.525850:0.524242:0.525850:0.018049:0.012604:0.007466:0.006523:0.005330:0.003625:0.012508:0.010660:0.012508:0.011738:0.006523:0.011699:0.013143:0.003848:0.003848:0.010314:0.008967:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.008967:0.007100:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.008967:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.006388
al with chemotherapy is 15 months) and :@0.524242:0.558050:0.920472:0.558050:0.920472:0.542294:0.524242:0.542294:0.013143:0.003848:0.008236:0.015990:0.003848:0.006523:0.011738:0.008236:0.012450:0.011738:0.012508:0.018049:0.012594:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.008236:0.003848:0.007466:0.008236:0.010660:0.010660:0.008236:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.007100:0.008236:0.013143:0.011738:0.013181:0.005330
may be candidates for second-line chem-:@0.524242:0.574493:0.915167:0.574493:0.915167:0.558737:0.524242:0.558737:0.018049:0.013143:0.010314:0.004560:0.013123:0.012508:0.004549:0.012450:0.013143:0.011738:0.013181:0.003848:0.013181:0.013143:0.006523:0.012508:0.007466:0.004549:0.006042:0.012604:0.005792:0.004541:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.003848:0.003848:0.011738:0.012508:0.004560:0.012450:0.011738:0.012508:0.018049:0.006388
otherapy. A number of chemotherapy :@0.524242:0.590937:0.920501:0.590937:0.920501:0.575181:0.524242:0.575181:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.013393:0.014239:0.013393:0.011738:0.011699:0.018049:0.013123:0.012508:0.005792:0.013393:0.012604:0.006042:0.013393:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
agents  has  clinical activity after  patients :@0.524242:0.607381:0.920474:0.607381:0.920474:0.591625:0.524242:0.591625:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.003237:0.011738:0.013143:0.007466:0.005330:0.003242:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.008582:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.008582:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.003231:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
have progressed on MVAC or GC.:@0.524242:0.623825:0.841376:0.623825:0.841376:0.608069:0.524242:0.608069:0.011738:0.013143:0.010660:0.012508:0.005330:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330:0.012604:0.011738:0.005330:0.017684:0.011153:0.014239:0.015644:0.005330:0.012604:0.005792:0.005330:0.016779:0.015644:0.005330
These agents include paclitaxel, doc-:@0.542426:0.640269:0.915170:0.640269:0.915170:0.624513:0.542426:0.624513:0.007812:0.011353:0.012123:0.007081:0.012123:0.014355:0.012758:0.012565:0.012123:0.011353:0.006138:0.007081:0.014355:0.003464:0.011353:0.012065:0.003464:0.011315:0.012796:0.012123:0.014355:0.012738:0.012758:0.012065:0.003464:0.003464:0.006138:0.012758:0.008852:0.012123:0.003464:0.004945:0.014355:0.012796:0.012219:0.012065:0.006388
etaxel, vinflunine, ifosfamide and oxaliplatin. :@0.524242:0.656713:0.920472:0.656713:0.920472:0.640957:0.524242:0.640957:0.012123:0.006138:0.012758:0.008852:0.012123:0.003464:0.004945:0.004029:0.010275:0.003464:0.011353:0.004474:0.004474:0.011315:0.011353:0.003464:0.011353:0.012123:0.004945:0.004029:0.003464:0.005657:0.012219:0.007081:0.005657:0.012758:0.017665:0.003464:0.012796:0.012123:0.004029:0.012758:0.011353:0.012796:0.004029:0.012219:0.008852:0.012758:0.003464:0.003464:0.012738:0.003464:0.012758:0.006138:0.003464:0.011353:0.005328:0.005330
None of these agents can, however, be :@0.524242:0.673157:0.920533:0.673157:0.920533:0.657401:0.524242:0.657401:0.013855:0.012219:0.011353:0.012123:0.010718:0.012219:0.005657:0.010718:0.006138:0.011353:0.012123:0.007081:0.012123:0.010718:0.012758:0.012565:0.012123:0.011353:0.006138:0.007081:0.010718:0.012065:0.012758:0.011353:0.004945:0.010718:0.011353:0.012219:0.015606:0.012123:0.010275:0.012123:0.003383:0.004945:0.010718:0.012738:0.012506:0.005330
considered as standard second-line thera-:@0.524242:0.689600:0.915167:0.689600:0.915167:0.673844:0.524242:0.673844:0.012065:0.012219:0.011353:0.007081:0.003464:0.012796:0.012123:0.005328:0.012123:0.012796:0.007639:0.012758:0.007081:0.007639:0.007081:0.006138:0.012758:0.011353:0.012796:0.012758:0.005290:0.012796:0.007639:0.007081:0.012123:0.012065:0.012219:0.011353:0.012796:0.006004:0.003464:0.003464:0.011353:0.012123:0.007639:0.006138:0.011353:0.012123:0.005407:0.012758:0.006388
py. Patients with advanced bladder cancer :@0.524242:0.706044:0.920516:0.706044:0.920516:0.690288:0.524242:0.690288:0.012738:0.009929:0.004945:0.004310:0.011007:0.012758:0.006138:0.003464:0.012123:0.011353:0.006138:0.007081:0.004310:0.015606:0.003464:0.006138:0.011353:0.004310:0.012758:0.012796:0.010275:0.012758:0.011353:0.012065:0.012123:0.012796:0.004310:0.012738:0.003464:0.012758:0.012796:0.012796:0.012123:0.005407:0.004310:0.012065:0.012758:0.011353:0.012065:0.012123:0.005788:0.005330
who have failed an initial chemotherapy :@0.524242:0.722488:0.920503:0.722488:0.920503:0.706732:0.524242:0.706732:0.015606:0.011353:0.012219:0.010102:0.011353:0.012758:0.010275:0.012123:0.010102:0.005657:0.012758:0.003464:0.003464:0.012123:0.012796:0.010102:0.012758:0.011353:0.010102:0.003464:0.011353:0.003464:0.006138:0.003464:0.012758:0.003464:0.010102:0.012065:0.011353:0.012123:0.017665:0.012219:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.010316:0.005330
regimen should be encouraged to partici-:@0.524242:0.738932:0.915169:0.738932:0.915169:0.723176:0.524242:0.723176:0.005328:0.012123:0.012565:0.003464:0.017665:0.012123:0.011353:0.007543:0.007081:0.011353:0.012219:0.011315:0.003464:0.012796:0.007543:0.012738:0.012123:0.007543:0.012123:0.011353:0.012065:0.012219:0.011315:0.005407:0.012758:0.012565:0.012123:0.012796:0.007543:0.006138:0.012219:0.007543:0.012738:0.012758:0.005407:0.006138:0.003464:0.012065:0.003464:0.006388
pate in clinical trials whenever possible.:@0.524242:0.755376:0.874550:0.755376:0.874550:0.739620:0.524242:0.739620:0.012738:0.012758:0.006138:0.012123:0.004945:0.003464:0.011353:0.004945:0.012065:0.003464:0.003464:0.011353:0.003464:0.012065:0.012758:0.003464:0.004945:0.006138:0.005407:0.003464:0.012758:0.003464:0.007081:0.004945:0.015606:0.011353:0.012123:0.011353:0.012123:0.010275:0.012123:0.005407:0.004945:0.012738:0.012219:0.007081:0.007081:0.003464:0.012738:0.003464:0.012123:0.005330
Immunotherapy  has  proven  survival :@0.542426:0.771820:0.920468:0.771820:0.920468:0.756064:0.542426:0.756064:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.013753:0.011738:0.013143:0.007466:0.005330:0.013768:0.013123:0.005715:0.012604:0.010660:0.012508:0.011738:0.005330:0.013760:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330
data in this setting. All five of the mAbs list-:@0.524242:0.788264:0.915094:0.788264:0.915094:0.772508:0.524242:0.772508:0.013181:0.013143:0.006523:0.013143:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.003848:0.007466:0.005330:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330:0.005330:0.014239:0.003848:0.003848:0.005330:0.004686:0.004686:0.010660:0.012508:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.018049:0.014239:0.013123:0.007466:0.005330:0.003848:0.003848:0.007466:0.006523:0.006388
ed above are approved by the FDA. The :@0.524242:0.804707:0.920516:0.804707:0.920516:0.788951:0.524242:0.788951:0.012508:0.013181:0.006850:0.013143:0.013123:0.012604:0.010660:0.012508:0.006850:0.013143:0.005715:0.012508:0.006850:0.013143:0.013123:0.013123:0.005721:0.012604:0.010660:0.012508:0.013181:0.006850:0.013123:0.010314:0.006850:0.006523:0.011738:0.012508:0.006837:0.009333:0.014316:0.014239:0.005330:0.006835:0.008197:0.011738:0.012508:0.005330
Keynote-045  trial   compared  pembroli-:@0.524242:0.821151:0.915147:0.821141:0.915147:0.805385:0.524242:0.805395:0.011372:0.012508:0.010314:0.011738:0.012604:0.006523:0.012508:0.006388:0.010660:0.010660:0.010660:0.005330:0.007803:0.006523:0.005792:0.003848:0.013143:0.003848:0.012436:0.005330:0.007803:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.005330:0.007803:0.013123:0.012508:0.018049:0.013123:0.005717:0.012604:0.003848:0.003848:-0.625682
17:@0.686467:0.815522:0.698897:0.815522:0.698897:0.806336:0.686467:0.806336:0.006215:0.006215
zumab :@0.524238:0.837585:0.593761:0.837585:0.593761:0.821829:0.524238:0.821829:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330
versus:@0.593376:0.837585:0.648967:0.837585:0.648967:0.821829:0.593376:0.821829:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 platinum-containing chemo :@0.648967:0.837585:0.920478:0.837585:0.920478:0.821829:0.648967:0.821829:0.004945:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.004945:0.012450:0.011738:0.012508:0.018049:0.012604:0.005330
and showed a 10.3 :@0.524238:0.854028:0.718644:0.854028:0.718644:0.838272:0.524238:0.838272:0.013143:0.011738:0.013181:0.009025:0.007466:0.011738:0.012604:0.015990:0.012508:0.013181:0.009025:0.013143:0.009025:0.010660:0.010660:0.005330:0.010660:0.005330
versus:@0.722339:0.854028:0.777930:0.854028:0.777930:0.838272:0.722339:0.838272:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 7.4 m OS, HR :@0.777930:0.854028:0.920516:0.854028:0.920516:0.838272:0.777930:0.838272:0.009025:0.010660:0.005330:0.010660:0.009025:0.018049:0.009025:0.016722:0.009583:0.005330:0.009025:0.013143:0.011680:0.005330
0.7, 95% CI 0.57-0.86.  The difference was :@0.524238:0.870472:0.920453:0.870472:0.920453:0.854716:0.524238:0.854716:0.010660:0.005330:0.010660:0.005330:0.008447:0.010660:0.010660:0.014913:0.008447:0.015644:0.004349:0.008447:0.010660:0.005330:0.010660:0.010660:0.006388:0.010660:0.005330:0.010660:0.010660:0.005330:0.005330:0.003133:0.008197:0.011738:0.012508:0.008447:0.013181:0.003848:0.006102:0.006042:0.012508:0.005711:0.012508:0.011738:0.012450:0.012508:0.008447:0.015990:0.013143:0.007466:0.005330
even bigger at 12 and 18 months, again :@0.524238:0.886916:0.920479:0.886916:0.920479:0.871160:0.524238:0.871160:0.012508:0.010660:0.012508:0.011738:0.007668:0.013123:0.003848:0.012950:0.012950:0.012508:0.005792:0.007657:0.013143:0.006523:0.007668:0.010660:0.010660:0.007678:0.013143:0.011738:0.013181:0.007678:0.010660:0.010660:0.007678:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.007662:0.013143:0.012950:0.013143:0.003848:0.011738:0.005330
demonstrating that if the immune system :@0.524238:0.903360:0.920472:0.903360:0.920472:0.887604:0.524238:0.887604:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.003848:0.011738:0.012950:0.007599:0.006523:0.011738:0.013143:0.006523:0.007607:0.003848:0.006042:0.007620:0.006523:0.011738:0.012508:0.007605:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.007607:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.005330
can be correctly activated longer-term :@0.524238:0.919804:0.920481:0.919804:0.920481:0.904048:0.524238:0.904048:0.012450:0.013143:0.011738:0.011141:0.013123:0.012508:0.011141:0.012450:0.012604:0.005792:0.005703:0.012508:0.012450:0.006523:0.003848:0.010314:0.011141:0.013143:0.012450:0.006523:0.003848:0.010660:0.013143:0.006523:0.012508:0.013181:0.011141:0.003848:0.012604:0.011738:0.012950:0.012508:0.005792:0.006388:0.006523:0.012508:0.006308:0.018049:0.005330
response is possible. :@0.524238:0.936248:0.713985:0.936248:0.713985:0.920492:0.524238:0.920492:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.003848:0.007466:0.005330:0.013123:0.012604:0.007466:0.007466:0.003848:0.013123:0.003848:0.012508:0.005330:0.005330